Besides PD-L1, tumor mutational burden (TMB) is also approved as a biomarker of ICIs therapy, such as pembrolizumab-based therapy and nivolumab + ipilimumab combination therapy, in pan-cancer (101–103). This evidence concerns the gene CD274 and neoplasm.